Ixebepilone, which sees very little use in 3rd line BCa from what I'm told, is likely the reason why this got hung up.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr